Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Its core argument still holds: trends run in equal and opposite directions simultaneously, and the consumer who trades up and trades down is not confused
Barchini J, Tchachaghian S, Shamaa F, Jabbur SJ, Meyerson BA, Song Z, et al
Clinical research suggests that multi-drug therapies often result in greater weight loss than single-drug therapies because they target different biological pathways
Because retatrutide does not currently hold a UK marketing authorisation, no MHRA-approved SmPC exists for this compound
As the competition is increasing day by day and we need to look smart as first impression of a person matters a lot